Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.

开发抗病毒治疗药物的临床前生物技术公司Eradivir已经完成了1025万美元的a轮融资。这笔资金将用于对其EV25流感治疗进行2a期挑战研究。